Tagged With Novartis

Dispensed: One Medical's stock market debut, a playbook for the gene therapy business, and a startup quietly powering the companies that ship prescriptions to your door


Dispensed: Hospital CIOs dish on the cloud, digital chiefs talk tech in healthcare, and how our editor picked his health plan


Dispensed: A trip to rural Pennsylvania, the final word on uBiome, and the looming cloud wars in healthcare



Dispensed: Amazon and Best Buy's expanding healthcare ambitions, the history of controversial e-cig startup Juul, and the lowdown on Novartis' letter to the FDA


Elizabeth Warren and Bernie Sanders just slammed the Swiss drug giant Novartis over a new controversy swirling around the world's most expensive drug


Dispensed: Insurers will now cover a $2.1 million drug for kids, the pharma industry's AI ambitions, and a caravan to Canada in search of cheaper insulin



Aetna and Anthem will now pay for more kids with a devastating rare disease to get a $2.1 million drug, reversing earlier denials


Dispensed: A big week for digital health IPOs, what happens when a $2.1 million drug can't get to the kids who need it, and what a top health-tech VC is looking to invest in


'Like we were being forced to gamble with our son's life': Health insurers won't pay for a $2.1 million drug for kids, and parents say they're running out of time


The US just approved a $2.1 million treatment for a devastating disease. It's the most expensive drug in the world.


Dispensed: Venture-backed insurance startup Bright Health's 2018 results, a dispute between 2 drug giants, and the quest for a male birth control drug


A top Novartis executive says the $225 billion drug giant is planning for a 'doomsday scenario' in cancer treatment



A revolutionary drug that could treat a rare and devastating disease is prohibitively expensive. But one state has a plan to pay for its potential $5 million price tag.


A huge lawsuit accuses nearly 20 big drug companies, a billionaire, and 2 brothers-in-law of cozying up to hike drug prices. Here's the inside story.


Tilray is soaring after announcing a deal with a unit of the Swiss drug giant Novartis to take its medical products global


Drug giant Novartis is gearing up to release a cheaper EpiPen rival, but one big factor may make competition tricky



A big pharma CEO said he was 'completely blindsided' by his company's deal with Trump's former lawyer


Novartis is going after a $5 billion market with a new treatment for vision loss. That's a big threat to Regeneron


Cancer-therapy provider Endocyte spikes 50% after Novartis agrees to buy it for $2.1 billion


Drugmakers are using an unusual tactic to compete in a new class of medication treating the 38 million Americans who have migraines